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Educational aims
●● To recognise the clinical and radiological presentation of the spectrum of diseases associated with 
bronchiectasis.
●● To understand variation in the aetiology, microbiology and burden of bronchiectasis and cystic 
fibrosis across different global healthcare systems.
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What is bronchiectasis?
Bronchiectasis is an anatomical description, refer-
ring to abnormal widening of the bronchi which 
may be caused by a wide range of inherited and 
acquired disorders [1–3].
Radiologically, bronchiectasis is most easily 
identified by computed tomography (CT) [3]. At 
any level, the diameter of the bronchi should be 
less than the adjacent blood vessel (known as 
the bronchoarterial ratio) [4]. An increase in the 
diameter of the bronchus, and a failure of the 
bronchus to taper normally as it goes out towards the 
periphery of the lung, is diagnostic of bronchiectasis. 
Other radiological features that may accompany 
bronchiectasis include bronchial wall thickening, 
mucus plugging, tree-in-bud abnormalities, air 
trapping, mosaicism and emphysema [4, 5]. None 
of these features are required for diagnosis.
Bronchial dilatation is cylindrical when mild, 
varicose when more severe and cystic when most 
severe (figure 1) [4–6].
When the term of bronchiectasis is used to refer 
to a disease rather than a radiological appearance, 
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Bronchiectasis is the term used to refer to dilatation of the bronchi that is usually permanent and is 
associated with a clinical syndrome of cough, sputum production and recurrent respiratory infections. 
It can be caused by a range of inherited and acquired disorders, or may be idiopathic in nature. The 
most well recognised inherited disorder in Western countries is cystic fibrosis (CF), an autosomal 
recessive condition that leads to progressive bronchiectasis, bacterial infection and premature 
mortality. Both bronchiectasis due to CF and bronchiectasis due to other conditions are placing an 
increasing burden on healthcare systems internationally. Treatments for CF are becoming more 
effective leading to more adult patients with complex healthcare needs. Bronchiectasis not due to CF 
is becoming increasingly recognised, particularly in the elderly population. Recognition is important 
and can lead to identification of the underlying cause, appropriate treatment and improved quality 
of life. The disease is highly diverse in its presentation, requiring all respiratory physicians to have 
knowledge of the different “bronchiectasis syndromes”. The most common aetiologies and presenting 
syndromes vary depending on geography, with nontuberculous mycobacterial disease predominating 
in some parts of North America, post-infectious and idiopathic disease predominating in Western 
Europe, and post-tuberculosis bronchiectasis dominating in South Asia and Eastern Europe.
Ongoing global collaborative studies will greatly advance our understanding of the international 
impact of bronchiectasis and CF.
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it describes a clinical syndrome of cough, sputum 
production and recurrent respiratory tract infec-
tions [1, 2, 7]. Dilatation of the bronchi leads to 
failure of normal mucociliary clearance, which may 
be exacerbated by abnormally thick mucus such as 
in cystic fibrosis (CF) [8–10]. The airways become 
colonised with bacteria, which promotes recruit-
ment of neutrophils and other inflammatory cells 
that further damage the airway through complex 
mechanisms that include the release of cytokines/
chemokines, proteases and antimicrobial peptides 
that combine to promote mucus hypersecretion, 
failure of bacterial killing, airway remodelling and 
failure of ciliary function [10–14]. This establishes 
“the vicious cycle of bronchiectasis”, which has 
been well described [13]. Whether failure of muco-
ciliary clearance, inflammation or infection occurs 
first to initiate the cycle is unclear, and it is likely 
the initiating event is different depending on the 
underlying cause of bronchiectasis [14–16].
What causes bronchiectasis?
The majority of cases of bronchiectasis are not 
due to CF, so-called non-CF bronchiectasis [17]. 
 Bronchiectasis therefore represents a final com-
mon pathway of a large number of disorders 
[15–19].
Post-infectious bronchiectasis occurs when 
bronchiectasis develops in adults or children 
following a severe infection [19]. This may arise 
following pneumonia, and is described fre-
quently following infection with Mycobacterium 
 tuberculosis. Non tuberculous mycobacteria (NTM), 
such as M. avium and M. abscessus, are strongly 
associated with  bronchiectasis and CF, although 
in the case of non-CF bronchiectasis is not always 
clear whether NTM is cause or a complication 
of bronchiectasis [20, 21]. Viral infections are 
also described as a cause of bronchiectasis [22]. 
 Bronchiectasis is an important complication of 
primary  immunodeficiencies such as common 
variable immunodeficiency, where it is presumed 
that recurrent infections lead to progressive 
lung damage [23]. It is important to be aware 
that, although typically presenting in children, 
 immunodeficiencies may be first diagnosed in 
adulthood.
A large number of connective tissue diseases 
(CTDs) have been associated with bronchiec-
tasis [24, 25]. The association between rheumatoid 
arthritis and bronchiectasis is well described, with 
2–10% of rheumatoid arthritis patients being 
affected. Sjögren’s syndrome, systemic lupus 
 erythematosus, ankylosing spondylitis, scleroderma 
and vasculitis have all been reported to have a higher 
incidence of bronchiectasis than that expected 
in the general population [24]. In many cases 
associated with CTD, the patient may be entirely 
asymptomatic. The significance of abnormal 
bronchial dilatation in the absence of symptoms 
in patients with CTD is unclear.
Inflammatory bowel diseases (IBD), both ulcer-
ative colitis and Crohn’s disease are associated 
with bronchiectasis [26]. Airway involvement in 
IBD is thought to be rare (reported at ∼0.2% in 
an IBD clinic) and progresses through chronic 
bronchitis, without radiological bronchiectasis, 
through inflammatory bronchorrhea (which can 
be very large volume, e.g. >100 mL⋅day−1) to clas-
sical bronchiectasis [26].
Allergic bronchopulmonary aspergillosis (ABPA) 
is an important cause of bronchiectasis to iden-
tify, because it has a specific treatment that can 
improve symptoms and prevent the development 
of severe bronchiectasis [27, 28]. Patients typi-
cally have a history of asthma (or CF) and present 
with cough and sputum (often with thick plugs 
and large volumes) with deteriorating symptoms 
of asthma including wheeze and exacerbations. 
Patients may have fleeting infiltrates on chest 
radiogrpahy with segmental, lobar or lung col-
lapse. The bronchiectasis is typically proximal, 
but this is not universal [1]. Diagnosis depends on 
demonstrating a specific hypersensitivity response 
a) b)
Figure 1 Radiological heterogeneity of bronchiectasis. Two patients are shown: a) a patient with moderate idiopathic 
bronchiectasis demonstrating predominantly cylindrical dilatation, and b) a patient with severe disease and Pseudomonas 
aeruginosa colonisation demonstrating widespread varicose and cystic bronchial dilatation.
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to Aspergillus fumigatus (or occasionally other 
fungi) on laboratory testing.
Inhaled foreign bodies, lung tumours and other 
obstructive lesions can cause localised bronchiec-
tasis, and consequently bronchoscopy is advised 
where bronchiectasis affects a single lobe [1].
There are a number of congenital or inherited 
causes of bronchiectasis, most of which are rare.
CF is an autosomal recessive condition affect-
ing 1–10 per 100 000 people across Europe. One 
in 25 Caucasians are carriers of mutations known 
to cause CF [29]. The carrier frequency in other 
ethnic groups is lower and consequently the 
prevalence of the disease is lower. It is a multi-
system disorder resulting from mutations in the 
cystic fibrosis transmembrane conductance reg-
ulator (CFTR) [30]. The majority of cases are now 
detected through newborn screening in Western 
countries, although diagnosis in adulthood in 
cases initially thought to be “non-CF” bronchi-
ectasis is not uncommon [1, 30]. CF should be 
excluded in all children presenting with bronchi-
ectasis and in adults presenting under the age of 
40 years, in those with upper lobe bronchiectasis 
(figure 2), in those with extrapulmonary manifest-
ations (malabsorption, pancreatitis or intestinal 
obstruction), and in those with Staphylococcus 
aureus, Pseudomonas aeruginosa or NTM [1, 2, 9].
CF has a special importance, because of the 
huge morbidity associated with the disease, 
which despite great advances in its treatment still 
has a life expectancy of only 40–50 years [31]. 
When it was first recognised as a distinct disease 
in 1938, patients with CF were expected to live 
only for a matter of months [32]. As antibiotic 
therapy and pancreatic enzyme replacement were 
developed in the mid-20th century, life expectancy 
and quality of life improved; however, these 
patients continued to die in adolescence or early 
adulthood. The past three decades of international 
translational research and refinement in the 
practice of caring for patients with CF, however, has 
resulted in further advances in nutritional therapy, 
targeted inhaled anti-pseudomonal agents 
and airway clearance, and most recently CFTR 
modulators that open the possibility of correcting 
the basic pathophysiological mechanism of CF 
[33]. The cumulative effect of such research 
and development is that many patients with CF 
can now expect to take on the tasks of everyday 
adult life such as finishing school, joining the 
workforce and starting families. CF is now a model 
of how  specialist care, translational research 
and inter action between healthcare providers, 
pharmaceutical industry and charities can drive 
improvements in life expectancy and quality of life 
for patients [8, 29–33].
Primary ciliary dyskinesia (PCD) is also an auto-
somal recessive disease [34]. The prevalence of the 
disease is unknown and likely to be greatly under-
estimated due to the absence of widely available 
screening tests. The disease may be diagnosed in 
childhood, or may be identified in late adulthood, 
with of cases reported beyond the sixth decade 
of life [35, 36]. The classical presentation of PCD 
includes childhood onset of respiratory symptoms, 
recurrent otitis media and sinusitis. Approximately 
half of patients with this classic presentation will 
have dextrocardia [35]. Other forms of congenital 
abnormalities may be present such as complex 
congenital heart disease, oesophageal atresia, 
biliary atresia or hydrocephalus. Infertility may 
be present. Young’s syndrome is a rare subset of 
PCD defining the combination of bronchiectasis, 
rhinosinusitis and reduced fertility (azoospermia).
α1-antitrypsin deficiency (AATD) lung disease is 
typically characterised by airflow  obstruction, but a 
significant number of patients have bronchiec tasis 
[37, 38]. ∼40% of patients have chronic  bronchitis 
and sputum production [37]. In one series from 
the UK of 74 subjects with PiZ AATD, 20 had 
 radiological and clinically significant  bronchiectasis 
[38]. Since bronchiectasis is typically not the only 
 feature of AATD, screening for AATD in unselected 
patients with bronchiectasis has limited value 
[39]. Nevertheless, AATD should be suspected in 
patients presenting at a young age with prominent 
emphysema and airflow obstruction, particularly in 
the presence of basal emphysema on CT [1].
Myeloma and haematological malignancy are 
rarely described in association with bronchiec-
tasis, but there is a perception that this group of 
patients are becoming more prevalent. McShane 
et al. [40] studied 16 patients with  haematological 
 malignancy in a US series. Cases associated 
with bronchiectasis included acute lymphocytic 
 leukaemia, chronic lymphocytic leukaemia, acute 
monocyte leukaemia, chronic monocytic  leukaemia, 
non-Hodgkin  lymphoma and Waldenstrom’s 
 macroglobulinaemia. Graft versus host disease fol-
lowing stem cell transplantation is a recognised 
cause of bronchiectasis, but in this series nearly half 
Figure 2 High-resolution CT scanning in a 27 year old 
patient with homozygous ΔF508 CF. Bilateral upper lobe 
bronchiectasis is evident, with mosaicism. The scan also 
showed extensive emphysema.
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of patients had not received stem cell transplanta-
tion and so it is likely defective immune function 
directly related to the haematological malignancy 
contributes to the development of bronchiectasis 
[40, 41]. All patients with bronchiectasis should be 
screened with a full blood count and measurement 
of serum immunoglobulins, which may detect pri-
mary and secondary immunodeficiency. Serum 
electrophoresis and Bence Jones protein in urine are 
used to screen for myeloma [1].
Gastro-oesophageal reflux disease (GORD) and 
aspiration are reported to be causes of bronchi-
ectasis, although this association has been poorly 
studied and it is difficult to ascertain to what 
extent GORD is a genuine aetiology because it is 
so prevalent in the general population. Some data 
suggests GORD may be a disease modifier more 
than an aetiology [42, 43].
HIV infection may predispose to bronchiec-
tasis through susceptibility to recurrent infec-
tions [44]. There is also a strong link between HIV 
infection and tuberculosis (TB) or NTM infection, 
both of which are strongly linked to bronchiectasis 
[44, 45]. In the era of highly active anti-retroviral 
therapy, opportunistic infections are less common 
but the impact of HIV on the immune response 
is also highly relevant. HIV patients have a higher 
prevalence of smoking that the general population 
and are more vulnerable to smoking-related lung 
damage and the development of chronic obstruc-
tive pulmonary disease (COPD) [45]. Therefore, in 
addition to being more susceptible to a number 
of disorders associated with bronchiectasis, even 
in the absence of these, patients with HIV appear 
to have a higher incidence of bronchiectasis than 
expected in the general population [46].
Yellow nail syndrome is a very rare orphan dis-
ease characterised by the triad of yellow nails, 
chronic respiratory disease and primary lymph-
edema (often presenting as pleural effusion). 
Males and females are equally affected and 
patients will usually develop symptoms in late 
childhood/early adulthood, although diagnosis 
may be delayed until very late in life. The triad 
is not always present, as nail changes can occur 
without respiratory involvement, and similarly 
lymphedema may be absent [47].
Mounier–Kuhn syndrome (also known as 
tracheo bronchomegaly) is a congenital disorder 
characterised by marked dilation of the trachea 
and proximal bronchiectasis. It is more frequent 
in men and often presents in early adulthood with 
typical symptoms of bronchiectasis, including 
recurrent infections, cough and sputum produc-
tion. It occurs due to atrophy of the elastic fibres 
of the trachea and main bronchi leading to tra-
cheobronchial flaccidity, dilatation and collapse. 
It is likely to have a genetic basis but a causative 
gene has yet to be identified (figure 3) [48].
Radiological bronchiectasis without symptoms 
should be differentiated from clinically significant 
bronchiectasis. Some studies report a very high rate 
of bronchiectasis in healthy nonsmokers. For exam-
ple, Winter et al. [49] conducted CT scans in 47 
healthy persons older than 65 years and 24 persons 
aged 30–50 years, and reported bronchiec tasis 
in 14.9% of those aged >65 years. In the oldest 
patients aged <75 years, 19.1% had  bronchiectasis. 
Matsuoka et al. [4] performed high-resolution CT in 
85 patients without known respiratory disease and 
reported the presence of bronchiectasis (defined 
as a bronchoarterial ratio >1) in 41% of subjects 
older than 65 years. Since none of these patients 
had symptoms, this suggests a very high frequency 
of asymptomatic mild bronchial dilatation in the 
elderly [4]. Bronchoarterial ratio increased with age 
and smoking also appeared to increase the ratio in 
the elderly population [4].
This list of causes is not exhaustive, but out-
lines both the most frequent causes of bronchiec-
tasis in children and adults while also emphasising 
the highly variable clinical presentation of these 
diseases (table 1). Despite extensive clinical, radio-
logical and immunological characterisation, as rec-
ommended by consensus guidelines, 30–70% of 
patients are classified as idiopathic bronchiectasis 
following testing [2–5].
What are the links with 
“traditional” airway diseases 
(COPD and asthma)?
There is overlap between COPD and asthma 
(sometimes referred to as asthma–COPD overlap 
syndrome (ACOS)) and there is clearly also overlap 
between bronchiectasis and COPD (sometimes 
called bronchiectasis–COPD overlap syndrome 
(BCOS)) [50–52]. A large proportion of patients 
with bronchiectasis will be initially diagnosed with 
COPD or asthma. In the recent series described by 
Quint et al. [53], using a large primary care data-
base in the UK to study the prevalence of bronchi-
ectasis, 42.5% of patients with bronchiectasis had 
a coexisting diagnosis of asthma and 36.1% had 
a coexisting diagnosis of COPD. Whether this rep-
resents genuine co-diagnosis, or whether there is 
a degree of misdiagnosis is unclear. There is clear 
overlap between these three disorders (figure 4); 
therefore, a patient presenting to primary care with 
a) b)
Figure 3 Two images from the same individual with tracheobronchomegaly showing a) gross 
tracheal dilatation and b) severe central bronchiectasis.
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cough, sputum production and airflow obstruction 
on spirometry is likely to be initially diagnosed with 
COPD, particularly if they have a smoking history 
[54]. Triggers for further investigation may be 
a failure to respond to standard treatment, fre-
quent exacerbations, large volume sputum pro-
duction, isolation of Gram-negative organisms 
in sputum, or severity of COPD that seems out of 
proportion to the reported smoking history [55]. 
The same applies to asthma where a high preva-
lence of bronchiectasis is likely to represent both a 
degree of misdiagnosis and coexistence of the two 
conditions at the same time as well as potentially 
chronic inflammation in asthma leading to the 
development of bronchiectasis [56, 57].
The prevalence of bronchiectasis in COPD 
patients is highly variable in the literature. The 
largest series such as the ECLIPSE cohort (n=2164) 
report a frequency of 5% in Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stage III 
and 7% in GOLD stage IV disease [58]. However, 
how bronchiectasis was radiologically defined in 
this cohort is not clear [58]. Another large cohort, 
COPDgene (n=3636), has reported a prevalence 
Table 1 Selected causes of bronchiectasis with their reported prevalence
Aetiology of bronchiectasis Proportion of adult patients 
affected
Typical clinical features
Idiopathic 20–60% Variable presentation
Post-infective 20–40% History of severe infection in the affected lobe(s) or historical 
infection#
Post-TB <2% in developed countries
Dominant cause in Eastern 
Europe, Asia and possibly 
other regions
History of TB with cavitation and lung damage
ABPA 1–10% History of asthma, sputum plugs, wheezing, response to 
corticosteroids and demonstration of specific allergy to 
Aspergillus
Central bronchiectasis
CTD 1–10% Evidence of systemic CTD (most frequently rheumatoid 
arthritis)
Immunodeficiency <5% May be evidence of nonpulmonary infections or unusual 
microorganisms
CF <1% in “non-CF” adult clinics Upper lobe bronchiectasis, extrapulmonary features, male 
infertility, malabsorption
Isolation of P. aeruginosa, S. aureus or NTM
PCD <2% but may be underestimated 
due to limited testing
Middle or lower lobe disease, history of otitis media and 
rhinosinusitis, early age of onset
Yellow nail syndrome <1% Yellow nails, pleural effusion
Tracheobronchomegaly <1% Characteristic radiological appearance of tracheal dilatation 
and central bronchiectasis
NTM infection 2–50% Middle lobe nodular bronchiectatic disease
More common in females
May be scoliosis, pectus excavatum and low BMI
HIV infection <1% No characteristic phenotype
Haematological malignancy <1% Frequent respiratory tract infections
AATD <1% Paraseptal emphysema, airflow obstruction
Inhaled foreign body <1% Single lobe disease
COPD¶ 2–60% Mild bilateral lower lobe disease with empysema and history 
of cigarette smoking
Asthma¶ 1–50% Not well described
Gastro-oesophageal reflux 
or aspiration¶
N/A Bilateral lower lobe or isolated right lower lobe bronchiectasis
Not clearly identified as an aetiology
BMI: body mass index; N/A: not available. #: reverse causation and recall bias make these estimates unreliable; ¶: whether these 
are true causes of bronchiectasis is debated. Prevalence rate data were extracted from [1, 12, 15–19].
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of 20.8% in COPD patients, with an association 
between radiological bronchiectasis and exacer-
bations and worse forced expiratory volume in 1 s 
(FEV1) [59]. While this may imply a high frequency 
of bronchiectasis, when put into the context of 
the study by Matsuoka et al. [4] (discussed earlier) 
suggesting 41% of asymptomatic healthy adults 
aged >65 years have radiological bronchiectasis, it 
cannot be said for certain whether COPD patients 
have a greater frequency of bronchiectasis than 
the general population [4].
Nevertheless, there is a consistent trend across 
multiple studies for bronchiectasis to be more 
frequent as airflow obstruction becomes more 
severe [60]. It has also been suggested that COPD 
and bronchiectasis together are associated with 
greater rates of bacterial colonisation and even 
death, although this is not a consistent finding 
and a recent meta-analysis pointed to some pub-
lication bias (where smaller studies with large 
effects were being preferentially published) [60]. 
Looking at this association from a bronchiectasis 
perspective, rather than from the point of view of 
COPD, where a bronchiectasis patient has airflow 
obstruction or a clinical diagnosis of COPD, there 
is a significantly increased risk of death demon-
strated across multiple studies [61–63].
There are less data available regarding asthma. 
Paganin et al. [57] performed high-resolution 
CT scanning on 70 patients with allergic and 56 
patients with non-allergic asthma. They demon-
strated cylindrical bronchiectasis in up to 80% 
of patients with severe non-allergic asthma 
and nearly 50% of patients with severe allergic 
asthma [57]. In patients with mild disease, the 
corresponding rates were ∼50 and ∼20%, respec-
tively. The authors concluded that bronchiectasis 
is common and related to the severity of asthma. 
Recently, asthma has been proposed as a con-
tributor to exacerbations of bronchiectasis [56]. 
Again, because asthma is common in the general 
population, it is difficult to determine to what 
extent asthma is a cause rather than a coexisting 
condition. Applying the Bradford–Hill concepts for 
causality, there remains much work to be done in 
this area (table 2).
The association between asthma and CF bron-
chiectasis is similarly unclear, as the overlap in 
symptomatology and variable airflow obstruction 
makes diagnosis challenging. Further obfuscating 
the diagnosis is the recognition of bronchial hyper-
responsiveness in CF cohorts and bronchiectasis 
cohorts [64, 65]. Despite this, many patients with 
CF and bronchiectasis are treated with inhaled 
corticosteroids and other typical asthma ther-
apies without well-established evidence of benefit 
[66]. Further research is needed to establish best 
 practices of care for these patients.
What is the clinical 
presentation of 
bronchiectasis?
Bronchiectasis has a highly variable clinical pre-
sentation, as it is a disorder that can affect any 
age from young children to the very elderly, males 
and females, and it is present in all ethnic groups. 
As such, it is not possible to describe a single 
typical clinical presentation. Some examples 
are discussed below which illustrate the clinical 
 heterogeneity of the condition.
Example 1
A 62-year-old woman, who is a lifelong nonsmoker, 
presents with a 5-year history of cough and sputum 
production. The symptoms have become worse 
recently. She was diagnosed with asthma and given 
an inhaled corticosteroid, which has had little effect. 
She improves with antibiotics, but her symptoms 
recur a few days after stopping antibiotics. Spirome-
try shows an FEV1 of 88% predicted, with no airflow 
obstruction. Sputum culture grows Haemophilus 
influenzae. A high-resolution CT is performed and 
shows bilateral lower lobe bronchiectasis.
Although it would be important in this case 
to exclude other possible causes of bronchiec-
tasis, this is the typical presentation of a patient 
with “idiopathic” bronchiectasis [1]. 60–80% 
of bronchiectasis patients are female, and pre-
sentation is very common between the ages of 
50–70 years [62, 63, 67]. The reasons for this 
preponderance in post-menopausal females are 
unknown. The delay in diagnosis is common. The 
good, but short-lived response to antibiotics is also 
a common feature that should raise suspicion of 
bronchiectasis [1].
Example 2
A 71-year-old woman, who is a lifelong non-
smoker, presents with a 2-year history of cough, 
COPD Asthma“ACOS”
“BCOS”
Bronchiectasis
Figure 4 Venn diagram illustrating the overlap between COPD, asthma and bronchiectasis.
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which was largely unproductive, and recent short-
ness of breath and weight loss. Her current BMI is 
18.3 kg⋅m−2. She undergoes a high-resolution CT 
scan which shows localised bronchiectasis in the 
right middle lobe with a nodular appearance. She 
produces two sputum samples that are negative 
for typical bacterial pathogens and grow no Myco-
bacteria. Nevertheless, due to clinical suspicion 
she underwent a bronchoscopy, with the wash-
ings isolating M. avium.
A high index of suspicion is required for NTM 
as it may present in patients without this typical 
“Lady Windermere syndrome” history. Patients are 
typically middle aged or elderly females and may 
have scoliosis and a low BMI [68]. The middle lobe 
or lingular bronchiectasis and nodular changes are 
classical, but are not required for diagnosis and so 
all patients with bronchiectasis should have spu-
tum tested for NTM at diagnosis and during a clin-
ical deterioration. Sputum cultures are sometimes 
negative for NTM even in those patients with active 
infection, either due to poor quality samples or low 
bacterial loads present; therefore, bronchoscopic 
sampling should be considered in patients with a 
high index of suspicion, as in this case [68].
Example 3
A 24-year-old man presents with cough and 
 sputum production and persistent rhino sinusitis. 
His chest radiograph is normal, but a high- 
resolution CT scan suggests bilateral bronchiec-
tasis. BMI is normal, and there is no suggestion 
of malabsorption and no history of neonatal dis-
tress or respiratory infections. There is no family 
history of respiratory problems. There is a history 
of recurrent otitis media during childhood leading 
to unilateral hearing loss.
This patient has PCD. Although it would be 
appropriate to exclude CF and immunodeficiency, 
the history of rhinosinusitis and middle ear infec-
tions is typical and these features are almost uni-
versal in some series of PCD. Although most cases 
will be detected in childhood it is important to 
have a high index of suspicion in patients present-
ing in early adulthood with bronchiectasis [69].
Clinical impact of 
bronchiectasis
Bronchiectasis has a major impact on patients in 
terms of symptoms, exacerbations and quality of 
life. In severe cases, bronchiectasis is also associ-
ated with a life expectancy shorter than that of the 
general population [70]. In specialist centres, ∼50% 
of patients will die from respiratory complications 
such as respiratory failure and respiratory infections, 
with 50% dying from nonrespiratory causes [62].
Mortality rates have been reported at 2–5% 
over 2 years, 10–30% at 5 years and up to 35% at 
15 years [61, 62, 70].
Patients may experience 0–12 exacerbations 
per year, with the average in most series being 
between one and three exacerbation per year 
[71–73]. Severe exacerbations requiring hospital 
Table 2 Bradford–Hill criteria for causality applied to the association between COPD, asthma and bronchiectasis
Bradford Hill criteria COPD Asthma
Strength of association/
effect size
Some studies report strong associations but 
may have methodological limitations
Strong association demonstrated
Consistency/reproducibility Reported by several studies with most 
reporting a high prevalence
Reported by several studies with most 
reporting a high prevalence
Specificity Lacking, as there are often other possible 
causes present
Lacking, as there are often other possible 
causes present
Temporality Rarely demonstrated Rarely demonstrated
Biological gradient Clearly demonstrated across multiple studies 
that as COPD becomes more severe 
bronchiectasis is more prevalent
Some evidence that bronchiectasis is more 
common in more severe asthma
Plausibility Both COPD and bronchiectasis are 
characterised by neutrophilic inflammation 
and share common features and therefore 
probably some common pathophysiology
Strong association between bronchiectasis and 
ABPA proves an association with eosinophilic 
inflammation, therefore association with 
asthma is highly plausible
Coherence Not fully testable Not fully testable
Experiment Experimental models of COPD are generally 
poor and conclusions cannot be drawn
Experimental models of asthma do not show 
features of bronchiectasis
Analogy COPD fits the model of the vicious cycle of 
bronchiectasis, being characterised by airway 
inflammation, infection and airway damage
Asthma fits the model of the vicious cycle of 
bronchiectasis, being characterised by airway 
inflammation, infection and airway damage
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admission and intravenous antibiotics have a 
greater impact in terms of healthcare costs, as 
well as in terms of long-term prognosis as they 
are associated with more significant lung function 
decline and increased mortality [62].
The St George’s Respiratory Questionnaire has 
been extensively used in bronchiectasis as in other 
respiratory diseases allowing a comparison of the 
burden of bronchiectasis to other disorders. In this 
sense, the quality of life impairment seen in bron-
chiectasis is equivalent to that observed in idio-
pathic pulmonary fibrosis or moderate-to-severe 
COPD [12].
The impact of bronchiectasis is highly variable. 
Mild disease is characterised by the absence of 
bacterial colonisation, infrequent exacerbations, 
less radiological extension and fewer symptoms. 
While features of severe disease include colon-
isation with P. aeruginosa, frequent and severe 
exacerbations, severe breathlessness and lung 
function impairment with more extensive radio-
logical disease [62, 74]. A scoring system incorpo-
rating these variables, named the Bronchiectasis 
Severity Index, has been developed to guide prog-
nostication in bronchiectasis and has been exten-
sively validated in Europe, China and in other 
healthcare systems [62, 75, 76].
While there is a move towards managing bron-
chiectasis is specialised clinics or centres in some 
countries, such as the UK, this is unusual in the 
majority of countries worldwide. Some patients 
with more severe bronchiectasis are cared for in 
CF clinics. A survey by the European Bronchiec-
tasis Network (EMBARC) of 231 European cen-
tres suggested that the majority (52%) managed 
patients in general respiratory clinics [77].
Clinical impact of CF
In the mid-20th century CF was recognised, but 
was usually fatal in early childhood because of a 
combination of respiratory infections and non-
pulmonary complications such as malabsorp-
tion and intestinal obstruction [8, 9]. Progressive 
improvements in care over time, including the 
development of pancreatic enzyme replacement, 
improved nutrition, systemic antibiotic treatment, 
mucoactive treatments and the recognition and 
treatment of infection with P. aeruginosa have 
driven remarkable improvements in life expec-
tancy [8, 9, 78]. Key to these developments has 
been the establishment of specialised care centres 
and robust standards of care [79].
CF is now in the process of changing from a 
predominantly “paediatric” disease to one where 
the major burden of care is in adults [9]. The 
median survival reported from the US and other 
national registries is ∼40 years, and is expected to 
rise further in the coming years [9].
Despite these improvements there remains 
a very high burden of disease and treatment 
associated with CF. Care is highly complex and 
multisystem including provision for nutrition/
dietetics, CF-related diabetes, CF-related liver dis-
ease, psychology, physiotherapy and all aspects 
related to the care of pulmonary complications. 
Complications of CF in adulthood are most fre-
quently pulmonary, and include severe exacerba-
tions, respiratory failure, pneumothorax, massive 
haemoptysis and requirement for lung transplan-
tation [8, 9, 79]. CF care requires centralisation 
and concentration of expertise. The European 
 Cystic Fibrosis Society standards of care describe 
the optimal make-up, size and facilities available in 
a specialist CF centre. Specialist CF centres should 
typically care for more than 100 patients [79].
Bronchiectasis and CF in 
Europe
Current prevalence estimates for bronchiectasis, 
excluding CF, are highly variable across different 
healthcare systems. German data report a rate 
of 67 per 100 000 while accepting this may be 
an underestimate [80]. Recent UK data suggests 
the condition is surprisingly common with rates 
of prevalence of 566 per 100 000 for women in 
the most recent year of data (2013). Rates were 
even higher when limited to the population aged 
>65 years, approaching 1% of the population [53]. 
Whether these UK data are applicable more widely 
across Europe is not known.
Data suggest that there is some variability 
regarding the aetiologies across Europe. Post- 
infectious bronchiectasis is the most commonly 
identified aetiology across European countries, 
although the data suggest that is more frequent 
in the southern countries (Greece, Italy and Spain) 
[16]. A recent analysis from Greece found that 
the leading cause of disease was post-TB, reflect-
ing the higher rates of TB prevalence in Eastern 
or South-east Europe compared with Western 
Europe, from where the bulk of publications on 
bronchiectasis have arisen to date [81–83].
CF is more prevalent in Europe, North America 
and Australasia, and occurs mainly in children 
of European descent [84]. Across the European 
countries, Ireland has the highest incidence rate, 
while the UK and Italy have also a high incidence 
of CF [85]. Eastern Europe (Poland, Bulgaria 
and  Romania) and Baltic countries (Latvia and 
Lithuania) have a much lower incidence [84, 85].
Bronchiectasis and CF in 
North America
There are more than 28 000 people in the USA 
with CF. These patients are cared for in regional, 
multidisciplinary CF centres accredited by the CF 
Foundation. Tremendous advances in diagnostics 
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and therapeutics over the past two decades have 
resulted in a shift in demographics in the USA 
such that the majority of patients with CF are now 
>18 years of age [86].
While patients with CF are generally cared for 
by centres accredited by a well-organised system, 
the majority of patients with non-CF bronchiec-
tasis in the USA are cared for by pulmonologists 
in settings varying from general pulmonary prac-
tice to dedicated, but not standardised, bronchi-
ectasis clinics. In 2007, the COPD Foundation 
Bronchiectasis and NTM Research Registry was 
established to better characterise the burden of 
disease in the USA and to coordinate research 
efforts. This collaborative initiative has approx-
imately a dozen participating sites including 
academic research institutions, which are refer-
ral centres for refractory or challenging cases 
and have particular experience in caring for 
 difficult-to-treat infectious aetiologies, such as 
NTM [87]. Earlier prevalence estimates of non-CF 
bronchiectasis in the USA were ∼52 per 100 000, 
which is close to the European Union definition 
of an orphan disease (50 per 100 000). More 
recently, Seitz et al. [88] reported a prevalence in 
the Medicare outpatient claims database of 370 
per 100 000, with the highest prevalence occur-
ring in females aged 80–84 years (prevalence of 
537 per 100 000).
The rates of NTM lung disease in patients with 
non-CF bronchiectasis in the USA have been 
highly variable, but are reported to range from 
10 to 30% with an overall increasing trend [89]. 
There may be some bias in these rates as data 
are collected from referral centres with regional 
expertise in caring for NTM disease. The rates of 
NTM in CF patients in the USA have been reported 
to range from 10 to 20% with considerable 
 geographic variation [90]
Bronchiectasis and CF in Asia
Bronchiectasis is a relatively common disease in 
the Asia-Pacific region. However, there is scant 
research interest and hence the true prevalence 
is unknown. The disease is underdiagnosed and 
many patients are diagnosed as COPD or asthma. 
The disease is thought to be more prevalent 
in those of lower socioeconomic status where 
immunisation rates are low [91, 92]. Bronchiec-
tasis is very common in indigenous Australians 
and particularly in children [93].
Hong Kong government statistics show a hos-
pital admission rate of ∼16.4 per 100 000, and 
the mortality rate was 1 per 100 000 population 
in 1990 [94]. Under-reporting is a major problem 
because bronchiectasis patients are treated pri-
marily on an outpatient basis.
Idiopathic disease still seems to be the com-
monest cause of bronchiectasis, as in the West, 
but there is a much higher rate of post-TB 
bronchiectasis in some Asian countries. Among 
100 patients with bronchiectasis analysed in 
Hong Kong 82% were found to have idiopathic 
disease and 8% had post-TB bronchiectasis [95]. 
The low rate of post-TB bronchiectasis reflects the 
effective TB control programme in Hong Kong. 
Preliminary data from the Indian bronchiectasis 
registry (EMBARC India; unpublished data) also 
shows that idiopathic disease is the most com-
mon cause, even though the incidence of post-TB 
bronchiectasis is much higher in India compared 
with Hong Kong. Epidemiological data from 
 Thailand shows that post-TB bronchiectasis is the 
most common cause in that country [96]. Stud-
ies emerging from Hong Kong, Busan in South 
Korea and EMBARC India show that P. aeruginosa 
is the commonest organism infecting the airways 
of patients with bronchiectasis [97]. M. avium 
complex pulmonary disease with nodules and 
bronchiectasis is also increasingly recognised in 
Asia including Japan [98]. NTM, which included 
M. kansasii and M. chelonae, were found in 6% of 
cases from Thailand [96].
Classical CF, with pancreatic insufficiency and 
progressive lung disease, is rare in the non-white 
population despite the greater presence of F508 
mutation among the indigenous South Asian 
population [99]. The prevalence of classical CF 
in Japan is 1 in 350 000, while sporadic cases 
have been reported from indigenous Sri Lankans, 
 Indians, Pakistanis, Chinese, American-Indians, 
black Africans, Malays and Arabs [100, 101].
Management
Treatment of bronchiectasis and CF is beyond the 
scope of this review. Nevertheless, the treatment 
of each can be considered in terms of correcting 
the underlying cause where possible, which in CF 
now includes the possibility to correct or modulate 
the underlying defect. Thereafter management is 
directed towards treatment of bronchial infection, 
including oral and inhaled antibiotics for stable 
disease and prompt treatment of exacerbations, 
anti-inflammatory therapy, and chest clearance 
including physiotherapy and mucoactive drugs. 
For further information there are several reviews 
and guidelines on these topics [1, 2, 79].
Future directions
Bronchiectasis and CF are rapidly developing 
fields. The epidemiology of bronchiectasis is being 
increasingly understood with a large contribution 
from registry initiatives worldwide. The European 
Bronchiectasis Registry (EMBARC) is a European 
Respiratory Society initiative to stimulate clinical 
research in this neglected field and has operated a 
registry since early 2015 [102]. At the time of writ-
ing more than 3000 patients have been enrolled 
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from more than 20 countries. Importantly, this 
initiative is also working with and supporting epi-
demiological research worldwide. This includes 
EMBARC India, the Indian bronchiectasis registry, 
which will generate the first population-based data 
on the characteristics and treatment of bronchi-
ectasis in South Asia, and the Australian Lung 
Foundation registry, which will provide important 
data in both adults and children from Australasia. 
In the USA, the US NTM and bronchiectasis registry 
has enrolled more than 2000 patients at the time 
of writing [87]. Such international efforts are build-
ing on the success and contribution of US and 
 European CF registries, which have been excep-
tionally important in understanding the natural 
history of CF and also in supporting randomised 
clinical trials of new therapies [103]. Ultimately 
the goal of all these epidemiological efforts must 
be to produce better standards of care and bet-
ter treatments for our patients. An EMBARC task 
force recently reported on 22 research priorities for 
bronchiectasis agreed between expert physicians and 
patients aimed at driving such improvements. These 
included better epidemiology, improved provision of 
care and priority randomised clinical trials [104].
Conclusion
Bronchiectasis is a radiological abnormality that is 
associated with a wide range of clinical disorders 
including infectious, inflammatory and congenital 
Self-evaluation questions
1 Regarding the aetiological diagnosis of bronchiectasis, which of the following is true?
a) Bronchiectasis affecting a single lobe is nearly always post-infectious
b) The only mandatory investigation for all bronchiectasis patients is serum immunoglobulin
c) CF should be excluded in all children and adults presenting with bronchiectasis
d) It is inappropriate to test for AATD in patients with bronchiectasis, regardless of the clinical presentation
e) NTM infection is strongly associated with bronchiectasis and it is important to rule out NTM in patients with bronchiectasis
2 Considering the impact of bronchiectasis, which of the following is false?
a) Exacerbations of bronchiectasis not due to CF account for a large proportion of the economic impact on the healthcare 
systems
b) As a result of the complex and multisystemic involvement of CF, treatment and follow-up care in specialist centres with 
multidisciplinary care teams is recommended.
c) The impact of bronchiectasis not due to CF is highly variable, with mild disease being characterised by infrequent 
exacerbations and the presence of P. aeruginosa colonisation
d) CF is no longer just the childhood disease it was years ago; today, the median survival is ∼40 years old
e) Airflow obstruction is associated with increased mortality in patients with non-CF bronchiectasis
3 A 26-year-old female presents for evaluation of a cough productive of thick mucus plugs, wheezing and difficult-to-control 
asthma. High-resolution CT demonstrates central bronchiectasis and bronchial wall thickening with mucus plugging to the right 
upper lobe. What is the test most likely to reveal the diagnosis?
a) Mannitol challenge test
b) Sweat chloride test and CF genetics
c) Serum total IgE and IgE to Aspergillus
d) Serum rheumatoid factor
e) Flexible bronchoscopy
4 A 37-year-old male presents with bilateral upper lobe bronchiectasis. He complains of persisting cough and large sputum vol-
umes. He developed symptoms in his early 20’s and was unsuccessfully treated for asthma with inhaled corticosteroids. He is 
married with no children and works in a factory. He gets brief relief from antibiotics but symptoms rapidly recur. The most recent 
sputum culture grew S. aureus. He denies any other medical history. What is the most likely underlying diagnosis?
a) NTM infection
b) HIV infection
c) Asthma associated bronchiectasis
d) CF
e) Common variable immunodeficiency
5 Which of the following statements regarding geographical associations is not true?
a) NTM infection is more common as a cause of bronchiectasis in the USA than in Western Europe
b) The most common cause of bronchiectasis in India is post-infectious bronchiectasis
c) CF is a disease primarily affecting persons of European descent
d) The incidence of bronchiectasis is high in indigenous Australians
e) Bronchiectasis is underdiagnosed in East and South-east Asia compared with Europe and North America
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disorders, including CF. Each individual disorder 
may be rare, but together the clinical problem is 
common and growing. All respiratory physicians 
should be aware of the clinical presentation and 
potential underlying causes of bronchiectasis in 
order to ensure appropriate early diagnosis and 
optimal treatment.
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